Oberreiter has served as Modulim’s Chief Operations Officer (COO) since 2014, successfully securing the funding necessary to launch the company’s first medical device – the Clarifi® Imaging System – targeted to podiatrists, vascular surgeons, interventionalists and wound care. Oberreiter is a highly successful and well-regarded business leader with more than 20 years of experience in leading medical device companies from development startup to full commercialization.
As the company expands its domestic and international sales of the Clarifi® Imaging System, Cuccia will focus on providing technical leadership, exploring strategic partnership opportunities, and ensuring technology alignment with the company’s business strategy.
“It’s a very exciting time for Modulim, and there is no better person to lead us than Richard,” said Cuccia. “He is a proven leader with the business vision, drive, and ability to expand revenue-generating and fundraising activities. He is exactly what Modulim needs as the company enters its next chapter of expanded product innovation and growth.”
“We greatly appreciate David’s vision and dedication in helping to bring this extraordinary technology to market. His passion for using optical technology to change healthcare delivery and save lives has shaped our culture, mission and vision,” said Oberreiter. “David will continue to be involved in the day-to-day decisions on the corporate governance, direction and priorities for the company and remain a resource to help lead and mentor its talented team. I am honored and excited to lead Modulim’s team forward driving towards expanding our customer base building on the solid foundation established by David.”
To learn more about Oberreiter’s experience, visit Modulim’s website at modulim.com.
Modulim is a pioneer in subsurface optical imaging powered by SFDI, an advanced imaging technique co-invented by founder and CTO David Cuccia, Ph.D. SFDI is a noninvasive tissue oxygen saturation technology that combines structured illumination with multiple wavelengths of light (visible and near-infrared) to allow for deeper and layer-specific assessment of tissue oxygenation and hemoglobin. This unique technology deciphers the reflection, absorbance, and scattering of light in tissue. The new Clarifi® Imaging System, powered by SFDI, is indicated for measuring tissue oxygenation in patients with potential circulatory compromise. It is easy and affordable for clinicians to integrate into their practice, with a Current Procedural Technology (CPT®) Proprietary Analyses (PLA) code (0061U).
For more information, visit modulim.com.